Open AccessAdverse Cutaneous Reactions to Hydroxychloroquine Are More Common in Patients With Dermatomyositis Than in Patients With Cutaneous Lupus Erythematosus
Author(s) -
Michelle T. Pelle,
Jeffrey P. Callen
Publication year - 2002
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archderm.138.9.1231
Subject(s) - hydroxychloroquine , dermatomyositis , medicine , dermatology , chloroquine , lupus erythematosus , connective tissue disease , systemic lupus erythematosus , adverse effect , autoimmune disease , immunology , disease , malaria , antibody , covid-19 , infectious disease (medical specialty)
Hydroxychloroquine sulfate and other antimalarial drugs have been used successfully as adjunctive therapy for patients with cutaneous lesions of dermatomyositis over the past 20 years. An increased incidence of cutaneous reactions to hydroxychloroquine has been postulated to occur in patients with dermatomyositis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom